Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.44 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.44 |
| ▸ | FDFT1 | P37268 | 10/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13776093 | 1.00 | CDYL2 (0.44) | CDYL2CDYLFDFT1TSHRSMN1; SMN2 | |
| SCHEMBL4117252 | 0.92 | CDYL2 (0.44) | CDYL2CDYLFDFT1TSHRMEN1 | |
| SCHEMBL4117260 | 0.92 | CDYL2 (0.44) | CDYL2CDYLFDFT1TSHRMEN1 | |
| SCHEMBL4117257 | 0.92 | CDYL2 (0.44) | CDYL2CDYLFDFT1TSHRMEN1 | |
| SCHEMBL4123398 | 0.92 | CDYL2 (0.46) | CDYL2CDYLFDFT1MEN1KMT2A | |
| SCHEMBL4710206 | 0.92 | CDYL2 (0.46) | CDYL2CDYLFDFT1MEN1KMT2A | |
| SCHEMBL4112411 | 0.92 | CDYL2 (0.46) | CDYL2CDYLFDFT1MEN1KMT2A | |
| SCHEMBL4112406 | 0.92 | CDYL2 (0.46) | CDYL2CDYLFDFT1MEN1KMT2A | |
| SCHEMBL4129636 | 0.92 | CDYL2 (0.43) | CDYL2CDYLFDFT1TSHRMEN1 | |
| SCHEMBL4710208 | 0.92 | CDYL2 (0.46) | CDYL2CDYLFDFT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | CDYL2 1908/4885CDYL 1152/4885FDFT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.